Lensar integrating phacoemulsification technology into adaptive cataract treatment system

the combined femtosecond laser and phacoemulsification system will be the first system to combine these technologies, changing the paradigm in cataract surgery. (Images courtesy of Adobe Stock)

Lensar Inc. today announced a step forward in its plans to integrate phacoemulsification technology from Oertli Instrumente AG, a Swiss manufacturer and industry leader in phacoemulsification, into the ALLY adaptive cataract treatment system.

According to a news release, Oertli filed an 510(k) with the FDA for its Faros device, which if cleared, will bring Lensar a step closer to deliver combined femto phaco technology.

Lensar noted in its news release the combined femtosecond laser and phacoemulsification system will be the first system to combine these technologies, changing the paradigm in cataract surgery.

The current ALLY system has quickly gained adoption among cataract surgeons for its advantages in efficiency and clinical results. Surgeons have the option of performing FLACS procedures in a completely sterile environment, moving from laser to phaco, saving between 8 and 10 minutes per procedure with ALLY. With the combined system surgeons will also save space in the operating room and optimize cataract surgery all on one system.

Nick Curtis, CEO of Lensar, said the company was pleased to bring the phaco technology, developed by Oertli, as an option to their customers.

“This combined system will be the first ever on the market, demonstrating our commitment to change the paradigm in cataract surgery,” he said in the company’s news release. “ALLY will offer even more ways for surgeons to optimize their workflow and improve the patient experience.”